Biotech stocks are fraught with high risk, but they also present high-reward opportunities for investors.
Let's take a look at some of the healthcare stocks that delivered double-digit returns since our reporting.
Want to know more about biotech stocks with high gains? Why not take a look at "52 Biotech Stocks Of 2022 With Triple-Digit Gains"?
Headlines
Published Date
Published Price
Maximum Price Since Publishing
Last Closing Price
Max Gain %
GOSS - Gossamer Bio Rallies On $120 Mln Investment By Institutional Investors
Jul. 13
$7.62
$15.20
$2.73
99.48%
APEN - Premarket Mover: Apollo Gains Weight On De Novo Marketing Authorization For Certain Devices
$5.17
$10.30
$9.97
99.23%
VIGL - Why Vigil Neuroscience Is Turning Heads
Sep. 22
$8.50
$16.77
$12.54
97.29%
BCLI - Brainstorm Plunges As FDA Refuses To Review ALS Treatment
Nov. 10
$1.20
$2.33
$1.92
94.17%
DCPH - Deciphering DCPH...
Apr. 26
$10.83
$20.88
$15.31
92.80%
SRTS - Sensus Healthcare Delivers Strong Q1 Results
May. 6
$7.92
$15.25
$6.42
92.55%
APEN - Apollo Endosurgery To Report Q2 Results On Aug.2
Jul. 25
$5.36
92.16%
VACC - Vaccitech To Report Additional Interim Efficacy Data On VTP-300 In Chronic HBV Infection Next Month
May. 16
$3.91
$7.45
$2.29
90.54%
KPTI - Will The Momentum Continue In Karyopharm?
Jan. 11
$7.75
$14.73
$3.10
90.06%
CLPT - ClearPoint Makes It Clear - Revenue And Footprint To Expand
Feb. 16
$8.93
$16.96
$8.40
89.92%
DAWN - Day One Skyrockets On Positive Study Results Of Tovorafenib In Pediatric Brain Tumor
Jun. 13
$14.94
$28.35
$21.42
89.76%
TRVI - Trevi Therapeutics' PRISM Trial Of Haduvio In Prurigo Nodularis Meets Goals
Jun. 29
$2.47
$4.68
$2.11
89.47%
ABCL - AbCellera Biologics - Waiting For Its Heyday…
May. 18
$14.97
$10.21
89.02%
RLMD - Relmada's REL-1017 Demonstrates Lack Of Abuse Potential In Second Study Too
Feb. 23
$20.50
$38.68
$3.37
88.68%
ISEE - IVERIC's Phase III Geographic Atrophy Trial Meets Goal, Shares Jump
Sep. 6
$12.96
$24.33
$22.32
87.73%
RVPH - Reviva - Waiting To RECOVER
Oct. 12
$3.25
$6.10
$3.75
87.69%
SIGA - SIGA Technologies Rallies As WHO Declares Monkeypox A Global Health Emergency
$14.45
$26.99
$7.64
86.78%
AGIO - Will Agios' Pyrukynd Secure Blockbuster Tag?
Jun. 23
$18.72
$34.76
$29.71
85.68%
ESPR - Will Esperion's Q1 Results Beat Estimates?
Apr. 21
$4.80
$8.87
$6.14
84.79%
BVNKF - Bavarian Back In Focus As Monkeypox Cases Rise
May. 20
$31.57
$58.02
$30.90
83.78%
OCUL - Ocular Therapeutix Q1 Results - Hit Or Miss?
May. 2
$3.57
$6.53
82.91%
ACCD - Accolade's Revenue For Q2 Of Fiscal 2023 To Grow 12% To 14%
Jul. 1
$7.55
$13.80
$8.46
82.78%
LABP - Landos - Bracing For A Busy Quarter Ahead
$0.75
$1.37
$0.26
82.67%
TCRT - Alaunos To Make Presentations At The International Cancer Immunotherapy Conference
Aug. 25
$2.20
$4.01
$0.59
82.27%
ZYXI - Zynex: What's Making News?
$7.99
$14.55
$13.32
82.10%
MCRB - When Will Microbiome Therapy Join The Recurrent C.diff Infection Armamentarium?
Sep. 2
$5.22
$9.49
$5.75
81.80%
OLK - Exploring Olink...
Jan. 21
$13.76
$24.93
$23.00
81.18%
ZLAB - Zai Lab Q1 Revenue Jumps More Than Twofold
May. 11
$30.00
$53.95
$32.59
79.83%
MDGL - Madrigal Pharma Reports Encouraging Data From NASH Trial; Shares Gain 15%
Jan. 31
$59.20
$105.93
$63.80
78.94%
BNR - Will Burning Rock Regain Ground?
Jun. 1
$2.40
$4.24
$2.55
76.67%
MASS - 908 Devices Sees Revenue Growing At 23-30% In FY22
Jun. 6
$14.76
$26.00
$8.49
76.15%
AMLX - Amylyx Pharma Ascends 16%
Jul. 5
$22.63
$39.78
$35.67
75.78%
ALDX - Aldeyra's Crossover Trial Of Dry Eye Disease Drug Achieves Goals; Stock Up Over 15%
Jul. 12
$4.55
$6.32
75.60%
XAIR - Beyond Air Breathes Easy
$6.70
$11.76
$6.17
75.52%
VERU - Veru Rises 17% On Submission Of EUA Application For Its Covid-19 Treatment
Jun. 7
$14.00
$24.55
$4.99
75.36%
CGEM - Cullinan Oncology Soars On Deal With Taiho Pharma
May. 12
$9.08
$15.89
$11.44
75.00%
PSTX - Poseida Inks Blockbuster Strategic Global Collaboration Agreement With Roche
Aug. 3
$3.68
$6.43
$0.81
74.73%
CANO - Cano Aiming For 75%-81% Revenue Growth In FY22
Jul. 7
$5.59
$9.75
$1.21
74.42%
KNSA - Kiniksa To Report Prurigo Nodularis Trial Data In 2H 2022
Jun. 22
$9.88
$17.20
$15.87
74.09%
PEAR - Will Pear Bloom?
$3.92
$6.74
$1.62
71.94%
TXMD - TherapeuticsMD Jumps On Receiving Equity Investment From Rubric Capital
Aug. 1
$6.81
$11.69
$7.09
71.66%
CUE - Cue Biopharma Rallies On Getting Fast Track Designation For Its Head And Neck Cancer Drug Candidate
Oct. 4
$2.45
$4.19
$2.70
71.02%
APLT - Applied Therapeutics To Present AT-007 Data At The Annual Clinical Genetics Meeting
Mar. 17
$1.60
$0.76
70.63%
RPTX - Repare Therapeutics Rallies In Pre-market On Collaboration With Roche For Camonsertib
Jun. 2
$10.97
$18.68
$15.34
70.28%
AHCO - AdaptHealth Looks Good, Can It Make You Rich?
Apr. 13
$16.20
$27.48
$19.75
69.63%
GH - Guardant Health's Revenue To Grow By 23% To 26% In 2022
May. 24
$37.00
$62.75
$30.06
69.59%
PTCT - PTC Therapeutics' Upstaza Just One Step Away From Getting Approval In Europe
$32.83
$55.58
$39.22
69.30%
STRO - Sutro Soars On Deal With Astellas To Advance Novel Immunostimulatory Antibody-drug Conjugates
Jun. 28
$4.98
$8.37
$7.30
68.07%
VIRX - Viracta Therapeutics Anticipates Data From Nana-val Trial In 2H 2022
Jun. 30
$3.43
$1.78
67.64%
ASRT - Assertio Expects 2022 Product Sales To Grow 16% To 24%
Mar. 28
$2.65
$4.44
$3.66
67.55%
FIXX - FDA Lifts Clinical Hold On Homology Medicines' Phenylketonuria Gene Therapy Trial
Jun. 14
$1.97
$3.30
67.51%
TSHA - Taysha Gene Awaits Regulatory Feedback For Gene Therapy TSHA-120
$3.07
$5.09
65.80%
MYNZ - Mainz Acquires Rights To Biomarkers With Potential To Enhance ColoAlert's Utility; Stock Rises
Jan. 5
$18.21
$1.08
64.74%
AURA - Throwing Light On Aura...
Jul. 8
$15.08
$24.83
$12.17
64.66%
DH - Definitive Healthcare Foresees 33% To 35% Revenue Growth In 2022
May. 27
$18.31
$30.11
$2.14
64.45%
MYOV - Myovant Sciences Gets Expanded FDA Approval For Myfembree; Stock Up
Aug. 8
$16.41
$26.93
$26.89
64.11%
PLRX - Premarket Mover: Pliant Therapeutics Soars On INTEGRIS-IPF Study Data
Jul. 11
$16.01
$26.25
$18.69
63.96%
ARDX - Will Ardelyx' Xphozah Make It To The Finish Line?
Oct. 13
$1.34
$2.19
$1.96
63.43%
HAE - Haemonetics Adds 15% On Reporting Q4 Profit, Beating Estimates
May. 10
$53.00
$86.58
$78.33
63.36%
RCKT - Rocket Pharma - Yet To Take Off...
Sep. 14
$14.11
$22.89
$22.24
62.23%
AUVI - Applied UV Soars As Its Distributor Gets Exclusive Deal In Pakistan
Jun. 9
$2.60
$4.20
61.54%
ATHX - Athersys To Provide Update On Clinical Programs On Feb.2
Jan. 27
$20.75
$33.25
$3.16
60.24%
BMEA - Biomea Fusion - What's In Store For 2022?
Jan. 4
$8.89
$14.20
$8.06
59.73%
DYN - Dyne Gearing Up For Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 Trials
Jul. 14
$9.79
$15.63
$13.52
59.65%
AXNX - Axonics On Track To Post Over 30% Revenue Growth In 2022
May. 26
$50.13
$79.92
$59.81
59.43%
RAD - Rite Aid Corp. Climbs 8% After Raising Annual Revenue Outlook Above Estimates
$7.29
$11.61
$4.27
59.26%
BTTX - Will BTTX See Better Days Ahead?
Apr. 5
$2.05
$3.23
$1.49
57.56%
TCDA - Will Veverimer Take The Crown As 1st Therapy To Treat Metabolic Acidosis And Slow CKD Progression?
Jun. 15
$8.80
$13.85
$0.17
57.39%
SGFY - Signify Health Sees Significant Momentum Heading Into H2
Aug. 5
$19.00
$29.88
$28.54
57.26%
MRUS - Will Merus Get A Boost From ENRGy Trial Data?
May. 31
$19.62
$30.81
$13.21
57.03%
OKYO - What's Making News At OKYO Pharma?
May. 25
$3.45
$2.26
56.82%
SNDX - Syndax Pharma - For The Long Haul
Mar. 2
$16.95
$26.51
$24.42
56.40%
CTIC - What's Making News At CTI BioPharma?
Apr. 6
$7.80
$5.71
56.31%
DCGO - A Quick Look At DocGo...
Feb. 10
$11.41
$6.94
56.30%
AXSM - Axsome Rises As Investors Cheer FDA Approval Of Major Depressive Disorder Drug
Aug. 19
$51.89
$80.87
$78.40
55.85%
DSGN - Is DT-216 Well-designed?
$16.89
$26.30
$8.76
55.71%
ESPR - Esperion - Waiting For A Clear Outcome
Jun. 21
$5.70
55.61%
NVNO - A Quick Look At EnVVeno Medical...
$5.10
$7.93
$5.23
55.49%
ASND - Will Ascendis Make An Ascent?
$86.55
$134.52
$118.60
55.42%
CRIS - Curis Rises On TakeAim Lymphoma, TakeAim Leukemia Data Presentation
$1.14
$1.77
$0.50
55.26%
INMD - InMode Up 12% As Prel. Results Come In Above Street View; Ups Guidance
$25.99
$40.29
$36.33
55.02%
PRAX - Praxis Precision To Report Aria Study Data In June
$8.60
$13.33
$2.28
55.00%
PRAX - Praxis At New Low As Study Of Its PRAX-114 For MDD Does Not Achieve Primary Goal
$4.89
54.75%
NTRA - Natera Expects 23% To 26% Revenue Growth In 2022
Apr. 19
$37.50
$57.88
$43.32
54.35%
PRCT - What's Driving PROCEPT BioRobotics' Revenue?
Jun. 27
$34.00
$52.40
$43.00
54.12%
AMEH - Apollo Medical Expects FY2022 Revenue To Grow 36% To 40%
Jun. 3
$37.69
$58.00
$31.14
53.89%
CUTR - Cutera Up On FDA Approval Of Its AviClear Acne Treatment Device
Mar. 25
$48.41
$74.38
$45.57
53.65%
AKYA - Akoya Biosciences To Report Q4 Results On Mar.14
Mar. 11
$10.79
$16.57
$12.22
53.57%
TCDA - Will Tricida Prove Its VALOR?
Sep. 23
$13.12
52.56%
OM - At The Outset...
$17.42
$26.48
$25.25
52.01%
RNAZ - TransCode To Advance Lead Candidate Into Clinical Trial In 2H 2022
Feb. 14
$2.03
$3.08
$0.43
51.72%
ALPN - Alpine Immune's Phase I NEON-2 Trial Placed On Partial Clinical Hold
Mar. 7
$6.82
51.25%
ALBO - Will Albireo Pharma Assert Its Position In Rare Liver Disease Drug Market?
Jan. 6
$24.91
$37.63
$20.29
51.06%
ADPT - Adaptive Biotechnologies Expects Nearly 20% To 26% Revenue Growth In FY22
$8.75
$8.01
50.97%
DRIO - What's Making News At DarioHealth?
Apr. 28
$5.11
$7.69
$3.98
50.49%
AGL - Why Agilon Health Is Worth A Look?
$18.85
$28.36
$17.23
50.45%
MPLN - MultiPlan Sees 4% To 10% Revenue Growth In 2022
$4.12
$6.19
$1.57
50.24%
EIGR - Eiger BioPharmaceuticals Soars On Positive Study Results From Its Covid-19 Treatment
$6.67
$10.02
$1.12
50.22%
NKTX - Nkarta To Report Additional Data For Two Engineered Natural Killer Cell Programs In 2H 2022
$12.31
$18.48
$7.03
50.12%
PYPD - Will PolyPid's SHIELDs Make A Mark?
Mar. 15
$4.60
$6.90
50.00%
LFMD - LifeMD Revenue Grows 60% In Q1
$2.15
$3.22
$2.27
49.77%
HARP - Harpoon To Report Phase I Data Of HPN328 In June
May. 13
$1.93
$2.89
$0.68
49.74%
EXAS - Exact Sciences - On An Accelerated Path To Profitability?
Nov. 7
$37.80
$56.52
$51.92
49.52%
ZYME - Zymeworks Inks Deal With Jazz As It Gears Up For Phase 3 Biliary Tract Cancer Trial Data
Oct. 19
$5.88
$8.73
#N/A
48.47%
EQRX - What's The Buzz At EQRx?
$4.08
$6.05
$2.18
48.28%
Feb. 4
$3.44
48.26%
TMCI - Treace Medical - Working Towards Establishing Lapiplasty As Standard Of Care For Bunion Treatment
Jul. 28
$16.90
$25.02
$22.95
48.05%
KMPH - KemPharm To Report Cardiovascular Safety Trial Data Of SDX In Q3
Apr. 25
$4.70
$6.92
$4.51
47.23%
REVB - Revelation Bio Bracing For A Busy Year?
$2.88
$0.21
46.94%
QDEL - QuidelOrtho Q3 Revenue To Beat Wall Street Estimates
$69.80
$102.00
$82.59
46.13%
PDSB - HUTCHMED's Gastric Cancer Trial Meets One Of The Two Primary Endpoints
Nov. 14
$10.06
$9.34
45.80%
ABIO - ARCA Biopharma Plunges As COVID-19 Trial Fails To Meet Primary Goal
Apr. 1
$2.59
$2.43
45.51%
PODD - Insulet Gets FDA Nod For Omnipod 5, The World's First Tubeless Automated Insulin Delivery System
Jan. 28
$220.00
$320.00
$298.99
45.45%
PRTK - Paratek Sees Demand Trends For Lead Drug NUZYRA To Continue
Aug. 4
$2.52
$3.65
44.84%
NOVN - Novan To File For Approval Of Molluscum Contagiosum Treatment In Q4
Jun. 16
$2.30
$3.33
$1.26
44.78%
SLGL - Sol-Gel Awaits Facelift
Jul. 15
$4.76
$6.89
$4.56
44.75%
OLMA - Olema To Present At The 34th EORTC-NCI-AACR Symposium
$2.85
$4.11
44.21%
TXMD - TherapeuticsMD To Divest VitaCare To GoodRx
$16.07
43.12%
SMTI - Sanara MedTech - Gaining Traction
Aug. 17
$28.00
$39.99
$39.10
42.82%
CTKB - Cytek Biosciences Expects FY22 Revenue To Grow 25%-31%
$11.26
$16.05
$10.49
42.54%
VOR - Vor Bio To Report Acute Myeloid Leukemia Trial Data In 2H22
$5.32
$7.57
$7.07
42.29%
TCMD - Tactile Systems Expects Revenue To Grow 13-15% In 2022
Feb. 24
$15.21
$21.62
$11.46
42.14%
VRDN - Viridian Catches Eyes
Aug. 15
$20.01
$27.95
$27.88
39.68%
GMDA - What's On Tap For Gamida This Year?
$3.38
$4.72
$1.22
39.64%
CLVS - Clovis Oncology Soars On Positive Data From Monotherapy Arm Of ATHENA Trial
Mar. 31
$0.08
39.48%
AUGX - Augmedix Expects Revenue Growth Of 43% To 44% In Q4
Feb. 2
$2.42
$1.15
39.26%
MRSN - Mersana Inks Option Agreement With GSK For Antibody-drug Conjugate XMT-2056; Stock Up
Aug. 9
$6.00
$8.34
$6.51
39.00%
CERT - A Second Look At Certara
Nov. 8
$13.30
$18.47
$16.17
38.87%
AMLX - Amylyx Pharma Gearing Up For FDA Decision
Sep. 27
$28.68
38.70%
ATXS - Astria Shines...
$9.31
$12.86
$11.81
38.13%
APYX - Premarket Mover: Apyx Medical Gets FDA Clearance For Renuvion APR Handpiece
Jul. 18
$8.12
$11.16
$2.00
37.44%
AMYT - Will Amryt Pharma's Q4 Results Lag Or Trump Estimates?
Mar. 8
$6.50
$8.90
36.92%
CDMO - Avid's Fiscal 2023 Revenue Expected To Increase 17% To 21%
$15.00
$20.47
$13.83
36.47%
MYNZ - Mainz Commences International Study Of ColoAlert, Results Expected By Early 2023
$13.67
$18.63
$7.08
36.28%
SLP - Simulations Plus To Report Q3 Financial Results On July 6
Jul. 4
$49.65
$67.59
$37.96
36.13%
HCA - HCA Healthcare Drops 8% On Lower Quarterly Profit, Revenue
Oct. 21
$183.58
$249.00
$239.05
35.64%
YMAB - Will Y-mAbs' Second Rare Disease Product Get FDA Nod?
$15.10
$20.48
$5.00
35.63%
PCVX - Vaxcyte Rallies On Pneumococcal Conjugate Vaccine Trial Results
Oct. 24
$35.15
$47.67
$45.80
35.62%
VKTX - Viking Therapeutics To Resume Phase Ib Trial Of VK0214 In X-ALD As FDA Lifts Clinical Hold
Jul. 19
$4.65
$4.02
34.78%
ARGX - Argenx' Phase 3 ADAPT-SC Trial In Generalized Myasthenia Gravis Hits Goals
Mar. 22
$302.91
$407.93
$385.81
34.67%
BLPH - How Soon Can Bellerophon REBUILD Itself?
$1.29
$1.73
$0.77
34.11%
TPST - What's Brewing In Tempest?
May. 9
$4.15
$1.36
33.87%
BIOL - Will BIOLASE Bring The Smile Back On Investors' Face?
$5.94
$0.62
33.78%
ZNTL - Zentalis Secures $25Mln Equity Investment
Apr. 27
$24.31
$32.34
$19.81
33.03%
HARP - Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation
$4.10
$5.45
32.93%
IMPL - NeuroMetrix Soars On Receipt Of Breakthrough Designation From FDA For Quell Technology
Jan. 19
$8.10
$10.75
$3.60
32.72%
BMRA - Biomerica's H. Pylori Antigen Test Awaits FDA Word
Oct. 3
$3.96
$5.25
$3.49
32.58%
LVTX - Lava Therapeutics To Present At J.P. Morgan Healthcare Conference Today
Jan. 12
$5.58
$7.38
32.26%
ALT - Altimmune Gears Up For NAFLD Trial Results
$17.87
$23.49
$11.48
31.45%
XERS - Xeris To Report Q1 Results Tomorrow
$1.88
31.38%
PRVB - MacroGenics Soars On Milestone Payment From Provention Bio For FDA Approval Of Teplizumab
Nov. 18
$7.50
$9.85
$9.28
31.33%
IRIX - For Your Eyes Only...
$2.66
$2.23
31.20%
CMAX - Care To Take A Look At CareMax?
Jul. 26
$6.48
$8.47
$3.13
30.71%
XGN - Will Exagen's Q2 Results Trump Or Miss Estimates
$6.87
$8.96
30.42%
AVXL - Anavex Life Clawing Back Yesterday's Loss?
$15.24
$8.64
30.37%
ELDN - Eledon Pharma To Report ALS Trial Data In June
May. 19
$3.04
$3.95
$2.49
29.93%
SAGE - Sage Therapeutics To Present LUMINARY Study Results Of SAGE-718 In Alzheimer's On Apr.5
$33.98
$44.07
$40.26
29.69%
HCAT - What's The Next Catalyst For HCAT?
$14.12
$18.30
29.60%
MXCT - MaxCyte - Encouraged By Ongoing Growth Of SPL Portfolio
Sep. 28
$5.82
$5.34
28.87%
ATEC - Alphatec - Gaining A Footing?
Feb. 17
$10.62
$13.65
$10.71
28.53%
PGNY - Premarket Mover: Progyny Soars On Upbeat Revenue, Outlook
$36.20
$46.50
$31.83
28.45%
EXEL - Will Exelixis Excel Or Flunk This Year?
Jan. 18
$18.24
$23.40
$15.94
28.29%
NKTR - Nektar Therapeutics Plunges On Disappointing Melanoma Trial Results
Mar. 14
$6.40
28.00%
AKYA - Is Akoya Biosciences A Good Bet?
$12.95
27.95%
MXCT - Time To Set Sight On MaxCyte?
$6.07
$7.76
27.84%
STVN - Stevanato Expects Nearly 11-12% Revenue Growth In FY22
$15.19
$19.41
$17.50
27.78%
CODX - Will Co-Diagnostics' Monkeypox PCR Test Pay Off?
$7.13
$2.53
BLFS - BioLife Sees Growth In Biostorage Services Platform In 2022 And Beyond
$21.11
$26.96
$17.58
27.71%
MDGL - Madrigal - Gearing Up For MAESTRO-NASH Data
Sep. 26
$64.99
$83.00
BTAI - Will Sales Of BioXcel's Agitation Drug Make A Splash?
$20.18
$20.05
25.58%
IPHA - Innate Pharma Awaits TELLOMAK Trial Data
$2.56
$3.20
$1.90
25.00%
ANGO - AngioDynamics Delivers Strong Q4 Results; Provides Upbeat Sales Outlook
$19.84
$24.74
$12.28
24.70%
COLL - Will 2023 Be A Banner Year For Collegium Pharma?
$18.74
$23.27
$22.75
24.17%
BGNE - BeiGene: What's Making News?
Jun. 24
$169.53
$210.51
$205.00
VLON - Vallon Pharma Flunks Pivotal ADHD Trial; Stock Plunges
Mar. 21
$2.16
$2.68
$0.30
24.07%
APLS - Premarket Mover: Apellis To Face FDA In November
$56.42
$70.00
EXEL - Exelixis Gains On Better-than-expected Quarterly Results
Feb. 18
$18.87
24.01%
AUTL - Will 2022 Be A Transformational Year For Autolus?
Mar. 9
$3.82
$4.73
$1.76
23.82%
MDXG - MiMedx - Expanding Placental Portfolio
$4.42
$2.95
23.81%
NAUT - What's Making News At Nautilus Biotech?
$5.07
$1.55
23.66%
ALEC - Alector - Pioneering Immuno-neurology
$10.93
$13.50
$9.07
23.51%
JANX - Janux Therapeutics - Transitions Into Clinical Stage
Oct. 20
$15.44
$19.05
$12.45
23.38%
DVAX - Dynavax Technologies - On Track For A Second Consecutive Year Of Profitability
$14.17
$17.48
$11.17
23.36%
SLS - SELLAS Life To Report Ovarian Cancer Trial Data In Mid-2022
$7.40
$2.35
23.33%
LEGN - Can Legend Carve Out A Niche For Carvykti?
$45.72
$56.25
$50.95
23.03%
AGTI - Agiliti Expects 12% To 14% Revenue Growth In 2022
$18.36
$22.53
$16.85
22.71%
MDRX - Allscripts Healthcare Rises As Prel. Q4 Revenue Better Than View, On Share Buyback
Jan. 25
$23.25
$17.78
22.37%
BBIO - A Walk Through BridgeBio
$10.34
$12.64
$9.26
22.24%
EXAI - Exscientia Soars On $5.2Bln Deal With Sanofi
Jan. 7
$20.24
22.23%
OSUR - OraSure - Growth For Sure?
$4.47
$5.46
$5.01
22.15%
ARQT - Arcutis Biotherapeutics: One Down, Four To Go
$22.44
$27.40
$15.96
22.10%
IMGN - ImmunoGen To Report Q2 Results On July 29
$5.43
$6.63
MMSI - This Stock Merits Attention
Oct. 27
$62.71
$76.14
$71.26
21.42%
AXGN - AxoGen Foresees Double-digit Revenue Growth In 2022
Sep. 16
$11.29
$13.66
$10.54
20.99%
HSTM - Will HealthStream's Q2 Results Trump Estimates?
$22.02
$26.62
$24.58
20.89%
RVMD - Revolution Medicines - Focusing On RAS-targeted Cancer Therapies
Nov. 25
$21.48
$25.72
$24.30
19.74%
CPRX - Catalyst Pharma Stock Hits All-time High
Sep. 9
$15.38
$18.39
$16.00
19.57%
BVS - Will Bioventus Walk The Talk?
Feb. 28
$12.63
19.56%
HRMY - Will Harmony Biosciences' Q3 Results Beat Estimates?
Oct. 28
$52.09
$62.09
$55.68
19.20%
FNA - Paragon 28 Sees 16%-19% Revenue Growth In FY22
Jul. 6
$17.75
$21.15
$20.14
19.15%
ADPT - Adaptive Biotechnologies - On Path To Profitability?
Nov. 4
$8.29
$9.87
19.06%
CASI - CASI Pharma - It's Not All About Evomela
Aug. 30
$4.86
18.54%
PPBT - Purple Biotech Recouping Some Of Yesterday's Losses?
Apr. 12
$3.00
$3.55
$1.59
18.33%
FNCH - Finch Therapeutics Through The PRISM…
Aug. 24
$0.69
17.96%
EIGR - Eiger BioPharma Awaits TOGETHER Trial Data Later This Month
$8.54
17.33%
ANIK - Anika To Report Q3 Results On Nov.8
$27.74
$32.51
$29.09
17.20%
CERT - Certara Expects FY22 Revenue To Grow Nearly 22% To 26%
$21.09
$24.66
16.93%
MYNZ - Mainz Biomed Up Over 12%; Here's Why...
$17.81
16.79%
MEDP - Medpace - At A Steady Pace
Oct. 25
$202.45
$235.72
$206.00
16.43%
MASI - Ardelyx' Chronic Kidney Disease Drug Scores Positive Recommendation From FDA Panel
Nov. 17
$129.91
$150.87
$142.59
16.13%
PHAT - Will Phathom Pharma's Vonoprazan Cross FDA Finish Line?
$17.19
$19.95
16.06%
ITCI - Intra-Cellular Therapies' Caplyta Sees Encouraging Uptake Trends
$52.65
$61.00
$51.05
15.86%
SNDX - Revisiting Syndax...
Sep. 20
$22.97
15.41%
AZYO - Aziyo Biologics Hits New High, What Next?
$7.82
$9.01
$3.64
15.22%
CGEN - Compugen To Present At The American Association For Cancer Research In April
15.16%
DMTK - Will DermTech Regain Its Lost Sheen?
Jul. 21
15.08%
LHDX - Lucira Expects Q4 Revenue To Grow Nearly Fourfold Sequentially
Feb. 9
$4.95
$5.67
14.55%
EIGR - Eiger Beckons Investors
$9.89
14.47%
CDXC - Will ChromaDex Walk The Talk?
$2.62
$2.99
$1.50
14.12%
CALT - Calliditas Announces Commercial Launch Of Kidney Disease Drug In The U.S.
$20.36
$23.01
13.02%
PDCO - Patterson Boosts EPS Outlook On Continued Strong Momentum
Mar. 4
$31.38
$35.29
$27.53
12.46%
AIRS - Will Q4 Results Help AirSculpt Technologies Get Back In Shape?
Mar. 10
$13.00
$14.60
$3.15
12.31%
TIL - Instil Bio - On Track
Aug. 12
$7.71
$0.58
12.23%
BTTX - Are Better Days Ahead For BTTX?
$2.50
$2.80
12.00%
ISO - Here's Why You Need To Watch IsoPlexis
Jul. 22
$3.84
$0.71
11.95%
CAPR - Capricor's Cell Therapy - A New Hope For Duchenne Muscular Dystrophy Patients?
Sep. 30
$6.58
11.90%
CVAC - CureVac Rises On Preclinical Study Data Of Bivalent Second-Generation MRNA Vaccine Candidate
$18.03
$20.06
11.26%
CUTR - This Key Player In Medical Aesthetics Market Sees 10-12% Revenue Growth In FY22
Dec. 1
$47.69
$52.89
10.90%
ACIU - AC Immune Awaits 4 Data Readouts
$1.94
10.61%
CSII - Can The Quarterly Results Lift Cardiovascular Systems' Share Price?
Nov. 1
$16.11
$14.51
10.34%
EGRX - Will The Recent Product Launches Add Wings To Eagle Pharma?
$48.88
$53.78
$29.33
10.02%
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.